Literature DB >> 29147770

[Infantile hemangioma of the eyelid].

F Lang1, U P Press2.   

Abstract

Hemangiomas are one of the most common vascular tumors in infancy. In most cases no therapy is necessary and spontaneous regression is observed; however, if they arise in the periocular region, immediate action is required as rapid growth frequently leads to obstruction of the visual field with the risk of developing amblyopia and orbital suppression up to permanent disfigurement and stigmatization of those affected. Novel pharmaceutical treatment options led to a significant paradigm shift in the treatment of pediatric hemangiomas.

Entities:  

Keywords:  Amblyopia; Orbital malformation; Propranolol; Ptosis; Vascular tumors

Mesh:

Year:  2017        PMID: 29147770     DOI: 10.1007/s00347-017-0604-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  10 in total

1.  Vincristine--an effective treatment of corticoid-resistant life-threatening infantile hemangiomas.

Authors:  Jaime Perez; José Pardo; Cristina Gomez
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

2.  Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.

Authors:  Kristen E Holland; Ilona J Frieden; Peter C Frommelt; Anthony J Mancini; David Wyatt; Beth A Drolet
Journal:  Arch Dermatol       Date:  2010-07

3.  Propranolol for severe hemangiomas of infancy.

Authors:  Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

4.  RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds.

Authors:  Hsien Chan; Catherine McKay; Susan Adams; Orli Wargon
Journal:  Pediatrics       Date:  2013-05-06       Impact factor: 7.124

5.  Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution.

Authors:  Suqin Guo; Nina Ni
Journal:  Arch Ophthalmol       Date:  2010-02

6.  Complications of systemic corticosteroid therapy for problematic hemangioma.

Authors:  L M Boon; D M MacDonald; J B Mulliken
Journal:  Plast Reconstr Surg       Date:  1999-11       Impact factor: 4.730

7.  A randomized, controlled trial of oral propranolol in infantile hemangioma.

Authors:  Christine Léauté-Labrèze; Peter Hoeger; Juliette Mazereeuw-Hautier; Laurent Guibaud; Eulalia Baselga; Gintas Posiunas; Roderic J Phillips; Hector Caceres; Juan Carlos Lopez Gutierrez; Rosalia Ballona; Sheila Fallon Friedlander; Julie Powell; Danuta Perek; Brandie Metz; Sebastien Barbarot; Annabel Maruani; Zsuzsanna Zsofia Szalai; Alfons Krol; Olivia Boccara; Regina Foelster-Holst; Maria Isabel Febrer Bosch; John Su; Hana Buckova; Antonio Torrelo; Frederic Cambazard; Rainer Grantzow; Orli Wargon; Dariusz Wyrzykowski; Jochen Roessler; Jose Bernabeu-Wittel; Adriana M Valencia; Przemyslaw Przewratil; Sharon Glick; Elena Pope; Nicholas Birchall; Latanya Benjamin; Anthony J Mancini; Pierre Vabres; Pierre Souteyrand; Ilona J Frieden; Charles I Berul; Cyrus R Mehta; Sorilla Prey; Franck Boralevi; Caroline C Morgan; Stephane Heritier; Alain Delarue; Jean-Jacques Voisard
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

8.  Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood.

Authors:  R R Ricketts; R M Hatley; B J Corden; H Sabio; C G Howell
Journal:  Ann Surg       Date:  1994-06       Impact factor: 12.969

Review 9.  Vincristine as a treatment for a large haemangioma threatening vital functions.

Authors:  S L Fawcett; I Grant; P N Hall; A W R Kelsall; J C Nicholson
Journal:  Br J Plast Surg       Date:  2004-03

10.  Oral atenolol therapy for proliferating infantile hemangioma: A prospective study.

Authors:  Yi Ji; Qi Wang; Siyuan Chen; Bo Xiang; Zhicheng Xu; Yuan Li; Lin Zhong; Xiaoping Jiang; Xiaodong Yang
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  10 in total
  1 in total

1.  [Corneal alterations in eyelid diseases].

Authors:  Elisabeth M Messmer
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.